Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

2.

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.

Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.

PMID:
30715161
3.

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.

Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M.

Eur J Cancer. 2019 Nov;121:202-209. doi: 10.1016/j.ejca.2019.09.001. Epub 2019 Oct 5.

PMID:
31593830
4.

New ESMO scale ranks mutations as cancer medicine targets.

Fricker J.

Lancet Oncol. 2018 Oct;19(10):e513. doi: 10.1016/S1470-2045(18)30664-8. Epub 2018 Aug 31. No abstract available.

PMID:
30177495
5.

Delivering on the promise of precision cancer medicine.

Berger MF, Van Allen EM.

Genome Med. 2016 Oct 25;8(1):110. No abstract available.

6.

Personalized Medicine: Genomics Trials in Oncology.

Hayes DF, Schott AF.

Trans Am Clin Climatol Assoc. 2015;126:133-43. Review.

7.

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F.

Ann Oncol. 2018 Jan 1;29(1):30-35. doi: 10.1093/annonc/mdx707.

PMID:
29140430
8.

Integrative omics analyses broaden treatment targets in human cancer.

Sengupta S, Sun SQ, Huang KL, Oh C, Bailey MH, Varghese R, Wyczalkowski MA, Ning J, Tripathi P, McMichael JF, Johnson KJ, Kandoth C, Welch J, Ma C, Wendl MC, Payne SH, Fenyö D, Townsend RR, Dipersio JF, Chen F, Ding L.

Genome Med. 2018 Jul 27;10(1):60. doi: 10.1186/s13073-018-0564-z.

9.

Targeted therapy in cancer.

Tsimberidou AM.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1113-32. doi: 10.1007/s00280-015-2861-1. Epub 2015 Sep 21. Review.

10.

Precision medicine in pediatric oncology.

Forrest SJ, Geoerger B, Janeway KA.

Curr Opin Pediatr. 2018 Feb;30(1):17-24. doi: 10.1097/MOP.0000000000000570. Review.

11.

A decision support framework for genomically informed investigational cancer therapy.

Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv098. doi: 10.1093/jnci/djv098. Print 2015 Jul. Review.

12.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J.

Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71. Review.

13.

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.

Xu C, Nikolova O, Basom RS, Mitchell RM, Shaw R, Moser RD, Park H, Gurley KE, Kao MC, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2018 Jun 15;24(12):2828-2843. doi: 10.1158/1078-0432.CCR-17-1339. Epub 2018 Mar 29.

14.

Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.

Molloy MP, Engel A.

Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1179-1181. doi: 10.1080/17474124.2018.1535897. Epub 2018 Oct 17. No abstract available.

PMID:
30791786
15.

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ.

Mol Cancer Ther. 2017 Dec;16(12):2645-2655. doi: 10.1158/1535-7163.MCT-17-0597. Review.

16.

Paul Workman: Drugging the Cancer Genome.

[No authors listed]

Trends Cancer. 2016 Oct;2(10):544-548. doi: 10.1016/j.trecan.2016.10.004. No abstract available.

17.

Pediatric oncology enters an era of precision medicine.

Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade Bender JL, Kim A, Laetsch TW, Irwin MS, Takebe N, Tricoli JV, Parsons DW.

Curr Probl Cancer. 2017 May - Jun;41(3):194-200. doi: 10.1016/j.currproblcancer.2017.01.002. Epub 2017 Feb 1.

PMID:
28343740
18.

Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.

Ortiz MV, Kobos R, Walsh M, Slotkin EK, Roberts S, Berger MF, Hameed M, Solit D, Ladanyi M, Shukla N, Kentsis A.

Pediatr Blood Cancer. 2016 Aug;63(8):1368-74. doi: 10.1002/pbc.26002. Epub 2016 Apr 15.

19.

Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).

Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel R.

Ann Oncol. 2014 Sep;25(9):1673-8. doi: 10.1093/annonc/mdu217. Epub 2014 Jun 20. No abstract available.

20.

An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.

Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, Tembe W, Keifer JA, Corneveaux JJ, Byron SA, Forman KM, Zuccaro C, Keats JJ, Lorusso PM, Carpten JD, Trent JM, Craig DW.

Pac Symp Biocomput. 2015:56-67.

Supplemental Content

Support Center